As a proof of concept, C3aR antagonists have shown therapeutic benefit in a number of rodent models of Alzheimer’s disease and other disorders which pathologies also imply deregulation of ECM turnover and complement activation60–63. The gene discussed is C3AR1; the disease is Alzheimer disease.